// App-Quantinova.ai

PB1998 : WEEKLY OPPOSED TO BI-WEEKLY BORTEZOMIB AS PART OF INDUCTION CHEMOTHERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA IS BETTER TOLERATED AND EQUALLY EFFICIENT: REAL-WORLD DATA FROM A RETROSPECTIVE AUDIT

Researchers

Presenter

  • Lucy Faulkner

Principal Investigators

  • Mamta Garg

  • Chandhini Suresh

Medical Centers

  • University Hospitals Leicester,Leicester,Reino Unido

  • University Hospitals Leicester,Leicester,Vereinigtes Königreich

  • University Hospitals Leicester,Leicester,Reino Unido

  • University Hospitals Leicester,Leicester,Соединённое Королевство

  • University Hospitals Leicester,Leicester,Vereinigtes Königreich

  • University Hospitals Leicester,Leicester,Storbritannien

  • University Hospitals Leicester,Leicester,Reino Unido

  • University Hospitals Leicester NHS Trust, Leicester, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Bortezomib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved